Open access
Open access
Powered by Google Translator Translator

Onco-hematology

M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.

23 Jun, 2022 | 10:10h | UTC

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis – Cochrane Library

Summary: Which combinations of medicines are best for the prevention and treatment of anaemia in people with cancer? – Cochrane Library

 


5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.

23 Jun, 2022 | 09:55h | UTC

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.

21 Jun, 2022 | 10:48h | UTC

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.

20 Jun, 2022 | 00:51h | UTC

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

 


10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.

20 Jun, 2022 | 00:49h | UTC

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Recommendations Statement: Diagnosis and treatment of systemic mastocytosis.

14 Jun, 2022 | 11:03h | UTC

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel – Hematology, Transfusion and Cell Therapy

 


Molecular international prognostic scoring system for myelodysplastic syndromes.

14 Jun, 2022 | 10:38h | UTC

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence

 


2-year follow-up of a single-arm study: Ciltacabtagene Autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma.

13 Jun, 2022 | 07:34h | UTC

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up – Journal of Clinical Oncology

Original Study: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

9 Jun, 2022 | 10:17h | UTC

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort – Blood

 


International consensus classification of mature lymphoid neoplasms.

9 Jun, 2022 | 10:15h | UTC

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee – Blood

 


Cardiac Magnetic Resonance Imaging–based screening for cardiac sarcoidosis in patients with atrioventricular block requiring temporary pacing.

8 Jun, 2022 | 10:41h | UTC

Cardiac Magnetic Resonance Imaging–Based Screening for Cardiac Sarcoidosis in Patients With Atrioventricular Block Requiring Temporary Pacing – Journal of the American Heart Association

Invited Commentary: Managing Patients With Advanced Atrioventricular Block: The Essential Role of Cardiovascular Magnetic Resonance Imaging for Timely and Accurate Diagnosis – Journal of the American Heart Association

 


ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.

7 Jun, 2022 | 10:52h | UTC

ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children – Radiotherapy & Oncology

 


Oncologic emergencies and urgencies: A comprehensive review.

6 Jun, 2022 | 12:06h | UTC

Oncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians

 

Commentary on Twitter

 


#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.

6 Jun, 2022 | 11:16h | UTC

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center

Commentary: Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma – The ASCO Post

 


#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.

6 Jun, 2022 | 11:11h | UTC

Teclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine

 

Commentary on Twitter

 


#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.

6 Jun, 2022 | 11:06h | UTC

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


Cohort Study: Risk of hematologic cancer in patients with undifferentiated pruritus.

30 May, 2022 | 10:35h | UTC

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live

 


Cohort Study: Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.

27 May, 2022 | 11:56h | UTC

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Editorial: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 


Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.

26 May, 2022 | 10:57h | UTC

Navigating financial toxicity in patients with cancer: A multidisciplinary management approach – CA: A Cancer Journal for Clinicians

Related:

Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared – JCO Oncology Practice

The high price of anticancer drugs: origins, implications, barriers, solutions – Nature Reviews: Clinical Oncology

Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer – Cancer

Financial toxicity: 1 in 3 cancer patients have to turn to friends or family to pay for care – STAT News 

Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR 

Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer

Financial Toxicity: Cancer Supportive Care Professionals Consider the Side Effects of Soaring Costs – ASCO Post

 


Second Revision of the International Staging System (R2-ISS) for overall survival in Multiple Myeloma.

26 May, 2022 | 10:34h | UTC

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project – Journal of Clinical Oncology

 


Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.

25 May, 2022 | 11:01h | UTC

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden – BMJ Open

News Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ

 

Commentary on Twitter

Under a http://creativecommons.org/licenses/by-nc/4.0/ license

 


Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile.

23 May, 2022 | 00:41h | UTC

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology

Commentary: Using a Transcriptomic Profile to Identify Plasma Cell Leukemia–Like Disease in Patients With Newly Diagnosed Multiple Myeloma – The ASCO Post

 

Commentary on Twitter

 


RCT: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma.

19 May, 2022 | 10:39h | UTC

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser

 

Commentary on Twitter

 


How I Treat series on plasma cell dyscrasias.

18 May, 2022 | 10:31h | UTC

Editorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood

How I treat relapsed multiple myeloma – Blood

How I treat frontline transplantation-eligible multiple myeloma – Blood

 


RCT: Fixed-duration Ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities.

16 May, 2022 | 01:47h | UTC

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities – NEJM Evidence

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.